Loading...

STSA - Satsuma Pharmaceuticals, Inc.

Top Biomed Signal for 06-25-2022
Top Biomed Stock Signal: STSA



Stock Signal Information


Signal

Top Biomed Stock
Report Date: 06-25-2022
Symbol: STSA - Satsuma Pharmaceuticals, Inc.
Sector:
Industry:
Top Biomed Stock Signal: STSA

  STSA Technical Chart

Company Contact

Satsuma Pharmaceuticals, Inc. (STSA)
400 Oyster Point Blvd Ste 221
South San Francisco, CALIFORNIA 94080
Phone: 14155050809
Website: https://www.satsumarx.com
CEO: Mr. John Kollins


Company Profile

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.